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Abstract Inclusion bodies are refractile, intracellular protein
aggregates usually observed in bacteria upon targeted gene
overexpression. Since their occurrence has a major economical
impact in protein production bio-processes, in vitro refolding
strategies are under continuous exploration. In this work, we
prove spontaneous in vivo release of both L-galactosidase and
P22 tailspike polypeptides from inclusion bodies resulting in their
almost complete disintegration and in the concomitant appear-
ance of soluble, properly folded native proteins with full
biological activity. Since, in particular, the tailspike protein
exhibits an unusually slow and complex folding pathway
involving deep interdigitation of L-sheet structures, its in vivo
refolding indicates that bacterial inclusion body proteins are not
collapsed into an irreversible unfolded state. Then, inclusion
bodies can be observed as transient deposits of folding-prone
polypeptides, resulting from an unbalanced equilibrium between
in vivo protein precipitation and refolding that can be actively
displaced by arresting protein synthesis. The observation that the
formation of big inclusion bodies is reversible in vivo can be also
relevant in the context of amyloid diseases, in which deposition of
important amounts of aggregated protein initiates the pathogenic
process. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Inclusion bodies (IBs) are major protein aggregates com-
monly occurring in recombinant bacteria when the expression
of plasmid-encoded genes is directed at high rates [1^3]. De-
spite some physiological factors in£uencing IB formation have
been identi¢ed [2], attempts to prevent protein aggregation are
in general unsuccessful [3]. Therefore, and since polypeptides
embedded in IBs are devoid of any biological activity and
therefore usefulness in a biotechnological context, refolding
procedures for in vitro protein recovery from puri¢ed IBs
are under continuous development [4^7]. On the other hand,
bacterial IBs are interesting and convenient models for dy-
namic and structural analysis of protein aggregation, that
could serve to better understand biological situations which
are di⁄cult to approach experimentally, such as protein de-
position in amyloid diseases. Despite this potential interest,
bacterial IBs, often viewed as an obstacle in bioproduction
processes, have been in general poorly investigated.
In this work, we prove that bacterial IBs are not inert
protein aggregates that undergo a parsimonious volumetric
grow by product accumulation, but on the contrary, the result
of an unbalanced equilibrium between in vivo protein aggre-
gation and solubilisation. Interestingly, this equilibrium can
be spontaneously displaced towards protein refolding when
protein synthesis is arrested, a situation that conducts to an
almost complete IB disintegration and to the appearing of
fully active protein forms. This fact can have a signi¢cant
impact on protein recovery when using bacteria as cell fac-
tory. In addition, it o¡ers new data about the general mechan-
ics of protein aggregation and an interesting model to monitor
protein aggregation and solubilisation in real time, a possibil-
ity that could be relevant also in the context of prionic and
other amyloid diseases.
2. Materials and methods
2.1. Bacterial strains, plasmids, proteins and culture conditions
The Lon3 Escherichia coli strain BL21 [8] and its LacZ3 derivative
BL26 were used for protein production. Plasmid pJVP1LAC is a
pJLA602 derivative that encodes a L-galactosidase fusion harbouring
the VP1 capsid protein of foot and mouth disease virus (FMDV) [9],
whose production is controlled by the lambda pR and pL lytic pro-
moters and the temperature-sensitive CI857 repressor. Plasmid
pTTSPA is a pTrc99 derivative that encodes a pseudo-wild-type
TSP protein (TSPA) with the full biological activities of TSP [10],
whose production is under the control of ptac promoter. Production
of both VP1LAC and TSPA in E. coli results in IB formation. Luria
Bertani (LB) medium [8] plus 100 Wg/ml ampicillin was used for cul-
ture of recombinant cells, and induction of gene expression was
achieved by temperature upshift from 28 to 42‡C for VP1LAC and
by IPTG addition (up to 1 mM) at 37‡C for TSPA. At di¡erent times
after induction of gene expression, protein synthesis was arrested by
chloramphenicol addition (up to 200 Wg/ml). In TSPA-producing cul-
tures, media were also washed by centrifugation to remove IPTG,
immediately prior to chloramphenicol addition. After chlorampheni-
col addition, pJVP1LAC-carrying cells were incubated at 28‡C to
allow a proper folding and activity of CI857ts repressor. For some
in vivo experiments, the strain JGT17, a vibp derivative of MC4100
[11] was also used.
2.2. IB analysis and puri¢cation and determination of protein activity
Procedures for numeric and volumetric IB analysis inside the cells
were already described [12], as well as the IB puri¢cation protocol by
repeated detergent treatment [13]. Since TSP IBs are rather smaller
than VP1LAC’s, in vivo analyses were done on 24 h- and 3 h-aged IBs
respectively. Soluble and insoluble cell fractions were analysed by
PAGE and proteins were detected in Western blot by using appropri-
ate sera. L-Galactosidase activity was determined according to Mill-
er’s method [14]. TSP activity was determined by plaque counting on
con£uent cultures of Salmonella typhimurium LT2 after incubating cell
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 0 7 3 - 7
*Corresponding author. Fax: (34)-93-5812011.
E-mail: antoni.villaverde@uab.es
FEBS 24526 19-1-01
FEBS 24526 FEBS Letters 489 (2001) 29^33
extracts and tailless P22 particles for assembling [10]. When required,
cells were disrupted by sonication as described [15]. For in vitro anal-
ysis, puri¢ed TSP and VP1LAC IBs (10U concentrated) from 3 h-
induced cultures, were incubated at about 1.3 Wg of protein per ml at
37‡C with 20U concentrated, sonic cell extracts from plasmid-free
BL26 cells at late exponential growth phase. These cells, were also
grown in LB medium at 37‡C as indicated above and shifted to 42‡C
at the middle exponential phase. Protease inhibitors PMSF (to 1 mM)
and benzamidine (to 2.5 Wg/ml) were also added. As a control, IBs
were incubated under the same conditions with the cell-free bu¡ers
used for further activity analysis, using Z bu¡er for VP1LAC IBs [14]
and TMBS for TSP IBs [10]. Samples were taken every 30 min for
activity analysis as described above, and soluble and insoluble protein
fractionation. Proteins in the obtained fractions were analysed by
Western blot. In the ¢gures, representative experiments are shown
from sets of four replicas.
3. Results
3.1. In vivo refolding of IB protein
In a previous work, we have shown a dynamic transition
between soluble and insoluble forms of L-galactosidase fusion
proteins in IB-forming cells, that might involve a signi¢cant
fraction of IB polypeptides and in which proteolysis is con-
nected [16]. Since it had not been still solved whether proteol-
ysis could be a mechanism of IB protein solubilisation or on
the contrary, it occurs over already solubilised polypeptides,
we have studied L-galactosidase enzymatic activity and IB
volumetric evolution after arresting the synthesis of the L-ga-
lactosidase fusion protein VP1LAC. Under these conditions,
both soluble protein (Fig. 1A) and L-galactosidase activity
(Fig. 1B) increase, concomitantly with a reduction in the in-
soluble VP1LAC fraction (Fig. 1A). Note that in a recombi-
nant L-galactosidase, that does not aggregate as IBs (protein
CO46), enzymatic activity is rapidly lost after the arrest of
protein synthesis (Fig. 1B) by degradation of the soluble
CO46. Moreover, in BL26/pJVP1LAC cells, a simultaneous
decrease of IB number and average volume is also observed
(Figs. 1C, D, 2, top). Altogether, these results strongly suggest
that IB-embedded protein is solubilised in vivo resulting in
disintegration of IB particles trough their progressive volu-
metric reduction. In addition, at least a fraction of IB protein
can reach the native conformation with fully biological activ-
ity, proving that proteolysis occurs on polypeptides previously
released by a proteolytic-independent process. The fact that in
an Ibp3 strain, in which IBs are also formed (not shown), L-
galactosidase activity is recovered as in the wild-type (Fig.
1B), suggests that IbpA,B proteins are not critical in this
refolding process.
In an additional approach to evaluate in vivo IB evolution
in a di¡erent expression system we monitored IB evolution in
cells producing P22 TSP protein IBs. TSP is a homotrimeric
protein that undergoes a complex folding pathway from
which unfolded intermediates collapse as IBs under overpro-
duction conditions [17,18]. In addition, TSP has been exten-
sively used as a model for the analysis of molecular interac-
tions between aggregated polypeptides [19] and of protein
folding and unfolding pathways [20^24]. The arrest of re-
combinant protein synthesis in IB-carrying cells results, as in
the case of L-galactosidase, in IB disintegration (Fig. 2, bot-
tom; Fig. 3D). Loss of TSP in the insoluble cell fraction can
be also monitored, as in the case of VP1LAC, by a numeric
IB reduction and a concomitant rise of TSP with full biolog-
ical activity (Fig. 3B). This indicates that the aggregated pro-
tein can be released from IBs in absence of protein synthesis
and transferred to the soluble cell fraction as TSP monomers,
that, also in absence of protein synthesis, can refold as fully
active TSP trimers. Note that a rapid increase in the trimeric
native form (Fig. 3B) is accounted by an initial lost of the
monomeric form from the soluble cell fraction (Fig. 3A) and
that a rate transition in the folding pathway between 1 and 2
h is coincident with the appearing of monomeric forms from
IB particles, that results again in a further folding rate tran-
sition at about 4 h. Some folding intermediates and degrada-
tion fragments have also been observed in blots (not shown).
Although it cannot be excluded that IBs formed by other
proteins could undergo alternative or less e⁄cient refolding
processes, the fact that two structurally di¡erent proteins are
released with a comparable e⁄ciency from IBs reveal an un-
expected context for protein aggregation in bacterial cells, in
which IB formation and growth must be regarded as the result
of an unbalanced equilibrium between protein synthesis and
aggregation. During production of misfolding-prone proteins,
bottlenecks in the protein folding assistant network would
conduct to deposition of unfolded and misfolded polypep-
tides, that would be progressively refolded upon chaperone
availability, a situation that is strongly favoured when the
de novo protein production is arrested.
Fig. 1. A: Presence of VP1LAC in the insoluble (black circles, left scale) and soluble (white circles, right scale) cell fractions from BL26 bacte-
rial cultures. The vertical line indicates chloramphenicol addition and temperature downshift. DU are densitometric units. B: L-Galactosidase
activity in bacterial cell cultures producing either VP1LAC (black squares, left scale) or CO46 (white squares, right scale). CO46 is a pseudo-
wild-type L-galactosidase not forming IBs. The activity in a VP1LAC-producing, IbpAB3 strain is also indicated (white triangles, left scale). U
are Miller L-galactosidase units [14]. C: Percentage of cells carrying either none (black bars), 1 (light grey bars), or 2 IBs (dark grey bars), in
BL21/pJVP1LAC from the same culture than in A and B. D: Variation in the average volume of remaining IBs. The induction time is indi-
cated in all the panels.
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3.2. In vitro refolding of IB protein
Some components of the bacterial folding assistant network
have been identi¢ed, although their sequential implication in
the cascade folding process is still under exploration [25^27].
Irrespective of the speci¢c factors acting on bacterial cells on
IB protein refolding, the possibility to induce in vitro protein
solubilisation from protein aggregates could be of interest in a
variety of purposes. In Fig. 4A, we show a rising of a major
VP1LAC degradation product (fragment B) [9] and a concom-
itant increase of L-galactosidase enzymatic activity by incuba-
tion of puri¢ed IBs in sonic extracts of E. coli cells. A simul-
taneous rising of intact VP1LAC is also observed by high
sensitive developing of blots (not shown), but the amount of
this species is too low for an accurate determination. L-Ga-
lactosidase activity is not detected when IBs are incubated in
saline bu¡er, although in some of these samples, low protein
Fig. 2. Micrographies of VP1LAC (top) and TSP (bottom) BL26 producing cells. Numbers indicate time in h after stopping the synthesis of re-
combinant proteins. The black bar represents 5 Wm.
Fig. 3. A: Monitoring of TSP monomer amounts after chloramphenicol addition (time 0) in insoluble (black circles, left scale) and soluble
(white circles, right scale) cell fractions. B: TSP activity monitored by phage rescue in the total cell fraction (black squares, left scale) and TSP
found in active, trimeric forms in the soluble cell fraction (white squares, right scale). C: Percentage of cells carrying either none (black bars),
1 (light grey bars), or 2 IBs (dark grey bars), in BL26/pTTSPA from the same culture as in A and B. Note that in A, the detection of mono-
mers in the insoluble cell fraction does not necessarily imply that TSP is actually in the monomeric form as embedded into IBs, since for elec-
trophoretic analysis of insoluble protein samples must be denatured before loading. D: Variation in the average volume of remaining IBs. The
induction time is indicated in all the panels.
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amounts were eventually observed in the soluble cell fraction
of some samples (not shown). The intact form of the soluble
enzyme in cell extract-treated IB samples is hardly detectable
in blots, and since the main degradation fragment is not
present in pure IBs [9], this indicates a rapid proteolysis after
the release of polypeptides from aggregates, in agreement with
the late fading of the enzymatic activity. On the other hand,
about 60% of IB protein is lost in about 2 h. In Fig. 4B, an
analogous increase of TSP phage rescuing activity is observed
in TSP IBs cell extract mixtures, simultaneously to a lost up to
40% of IB protein. Again, the late decrease of TSP activity
and concentration of soluble TSP indicates further protein
degradation.
4. Discussion
Since early studies on bacterial physiology, IBs were be-
lieved to be compact protein aggregates of unfolded polypep-
tide chains, that being unreachable by proteases and chaper-
ones, remain inert once produced in the cell [1,28]. However,
it has been observed enzymatic activity associated to some
enzyme-based IBs [29,30] and also the presence of native-
like secondary structure in IB protein [31]. In addition, the
¢nding of di¡erent conformational states within IB particles
[32] has been very recently con¢rmed by combining scanning
electron microscopy and kinetic modelling of in vitro IB tryp-
tic digestion [13]. These observations indicate that as in the
case of amyloid ¢brils, IBs might be formed by a range of
folding intermediates rather that by completely unfolded
chains.
Even more intriguing is the observation of a dynamic pro-
tein transition between soluble and insoluble cell fractions
during volumetric IB growth in vivo [16], that appeared to
be linked to the proteolytic digestion. By exploring this event
in both a L-galactosidase fusion (VP1LAC) and P22 TSP, we
prove here that IB growth is the result of an unbalanced equi-
librium between protein precipitation and cell-mediated re-
folding and solubilisation, that can be spontaneously redi-
rected towards body disintegration by arresting the synthesis
of the recombinant polypeptide. Under this situation and
when IBs had been already formed, their number and volume
rapidly decrease in living cells (Figs 1, 2 and 3), concomitant
with a transition of the target protein from the insoluble to
the soluble cell fraction and a protein refolding process to
gain full functionality. Note that TSP folding is a specially
long and complex molecular process [17] to reach deep L-sheet
interdigitation between subunits [33]. In the view of these
results, it seems reasonable to speculate that components of
the bacterial folding assistant network are able to act over
aggregates of misfolded protein prompting protein release
and correct protein folding from IBs. This solubilisation pro-
cess is eclipsed when protein synthesis is directed at high rates,
but becomes evident when de novo synthesis is arrested. How-
ever, note that in both in vivo and in vitro situations, a small
protein amount remains insoluble after prolonged experi-
ments, a fact that could be in agreement with the observation
of a heterogeneity in the molecular organisation of IB poly-
peptides as recently described [13]. It is worthy to note, that
whereas TSP IBs are homogeneously a¡ected by protein sol-
ubilisation (Fig. 3D), recalcitrant species of aggregated
VP1LAC seem to be heterogeneously distributed among IBs
in the bacterial culture, since a small fraction of these particles
displays essentially the same volume in absence of protein
synthesis (Fig. 1D). This observation could indicate that dif-
ferent polypeptides can be packaged in di¡erent organisation
patterns within IB particles.
Independent approaches have proved that chaperones can
prevent protein aggregation in di¡erent cellular contexts and
also favour in vivo solubilisation from aggregates from di¡er-
ent origin [34^40]. However, as far as we know, bacterial
inclusion bodies have not been explored in this context and
its transient nature never reported, despite being extremely
common and inconvenient in recombinant bacteria. The
data presented here indicate that IB formation is not a
dead-end process in the protein quality network [41] of bac-
terial cells, but a transient situation in which IBs act as a
reservoir of misfolded polypeptide chains, over which cell
components can still apply its folding assistant potential.
The fact that IB solubilisation can also be done in vitro by
using cell extracts (Fig. 4), o¡ers intriguing possibilities to
solve or diminish one of the main bottlenecks in the use of
bacteria as a cell factory for foreign proteins, namely IB for-
Fig. 4. A: L-Galactosidase activity (right scale) from VP1LAC IBs
incubated with crude cell extracts (black triangles) or with saline
bu¡er (white triangles). Protein amounts (left scale) in the insoluble
(black circles) and soluble (white circles) cell fractions are also indi-
cated. Whereas the insoluble protein corresponds to the intact
VP1LAC, the soluble fraction is mainly composed by a major deg-
radation fragment of 90 kDa [9]. B: TSP activity as monitored by
infectious phages rescued from P22 tailless particles (right scale), in
TSP IBs incubated with crude cell extracts (black triangles) or with
saline bu¡er (white triangles). Protein amounts (left scale) in the in-
soluble (black circles) and soluble (white circles) cell fractions are
also indicated. Intact TSP monomers are the main component of
the soluble cell fraction.
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mation. More importantly, the fact that protein aggregation
can be reverted even from poorly structured elements such as
IBs prompts to deeply scrutinise possibilities for therapeutic
approaches to amyloid diseases based on the reversion of the
aggregation process. This possibility is specially appealing
since the recent report that chaperones can act as neurode-
generative repressors [35,36] and modulators of ¢bril forma-
tion [37].
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